Clinical Trial Update: A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) [Phase 3]

View source ↗

Summary

A Phase 3 ADEPT-4 study evaluating KarXT for psychosis associated with Alzheimer's disease is currently recruiting. Sponsor Karuna Therapeutics (a Bristol Myers…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Alzheimer Disease | Phase 3 | Status: RECRUITING